Back to search results

MIST Trial: Investigating ECC4703 and Semaglutide for Obesity

This study, called the MIST Trial, is looking into how well two different medications, ECC4703 and Semaglutide, help adults with obesity manage their weight. Researchers want to see if ECC4703 can reduce body weight and, in a smaller group, if it can also reduce liver fat. You might be able to join if you are between 18 and 75 years old, have a body mass index (BMI) of 30 or higher, and meet other health requirements, including a specific kidney function level (eGFR). The study will measure changes in body weight and liver fat content over 20 weeks. The current recruitment status is unclear, and the study plans to enroll 151 participants.

Study design
This is an interventional study, meaning participants will receive either ECC4703, a placebo (an inactive substance), or Semaglutide. It aims to enroll 151 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary measurements for body weight and liver fat content are taken from Baseline (Week 9) to Week 20.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07505303

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

Active, Not Recruiting
PHASE2Ages 18–75InterventionalTreatment
Eccogene
~151 participants
Updated 2026-06-25 on ClinicalTrials.gov
What's tested:ECC4703PlaceboSemaglutide

At a glance

Recruiting sites
0 of 15 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage Change in Body Weight from Baseline (Week 9) to Week 20
Measured over Baseline (Week 9) to Week 20
+4 more outcomes measured

Conditions

Adult Obesity
Weight Management

Explore related trials

Obesity

Where it's being run

15 sites across 10 states
Texas3
California2
Florida2
Georgia2
Alabama1
Minnesota1
Nebraska1
North Carolina1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Percentage Change in Body Weight from Baseline (Week 9) to Week 20Baseline (Week 9) to Week 20
  • Proportion of Participants Achieving ≥5% Reduction in Body Weight from Baseline (Week 9) to Week 20Baseline (Week 9) to Week 20
  • Absolute Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic SteatosisBaseline (Week 9) to Week 20
  • Percentage Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic SteatosisBaseline (Week 9) to Week 20
  • Proportion of Participants With ≥30% Relative Reduction in Liver Fat Content as Measured by MRI-PDFFBaseline (Week 9) to Week 20